Calliditas Therapeutics AB (publ) (CALTX.ST)
SEK 208.0
(0.87%)
SEK 208.0
(0.87%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.2 Billion SEK | 50.32% |
| 2022 | 802.87 Million SEK | 250.07% |
| 2021 | 229.34 Million SEK | 26141.08% |
| 2020 | 874 Thousand SEK | -99.53% |
| 2019 | 184.82 Million SEK | 0.0% |
| 2018 | - SEK | 0.0% |
| 2017 | - SEK | -100.0% |
| 2016 | 497 Thousand SEK | 3.97% |
| 2015 | 478 Thousand SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 295.48 Million SEK | -34.56% |
| 2024 Q2 | 559.78 Million SEK | 89.45% |
| 2023 Q1 | 191.35 Million SEK | -55.4% |
| 2023 FY | 1.2 Billion SEK | 50.32% |
| 2023 Q4 | 451.56 Million SEK | 53.28% |
| 2023 Q3 | 294.59 Million SEK | 9.36% |
| 2023 Q2 | 269.38 Million SEK | 40.78% |
| 2022 Q4 | 429.04 Million SEK | 64.98% |
| 2022 Q2 | 64.04 Million SEK | 28.78% |
| 2022 Q1 | 49.73 Million SEK | 59.51% |
| 2022 FY | 802.87 Million SEK | 250.07% |
| 2022 Q3 | 260.05 Million SEK | 306.04% |
| 2021 Q4 | 31.18 Million SEK | -84.27% |
| 2021 Q1 | - SEK | -100.0% |
| 2021 Q2 | - SEK | 0.0% |
| 2021 FY | 229.34 Million SEK | 26141.08% |
| 2021 Q3 | 198.16 Million SEK | 0.0% |
| 2020 Q1 | 474 Thousand SEK | -98.98% |
| 2020 Q2 | - SEK | -100.0% |
| 2020 FY | 874 Thousand SEK | -99.53% |
| 2020 Q4 | 400 Thousand SEK | 0.0% |
| 2020 Q3 | - SEK | 0.0% |
| 2019 Q4 | 46.58 Million SEK | 0.0% |
| 2019 Q2 | 138.24 Million SEK | 0.0% |
| 2019 Q3 | - SEK | -100.0% |
| 2019 FY | 184.82 Million SEK | 0.0% |
| 2019 Q1 | - SEK | 0.0% |
| 2018 Q4 | - SEK | 0.0% |
| 2018 FY | - SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 Q1 | - SEK | 0.0% |
| 2017 Q3 | - SEK | 0.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2017 Q4 | - SEK | 0.0% |
| 2017 FY | - SEK | -100.0% |
| 2016 FY | 497 Thousand SEK | 3.97% |
| 2015 FY | 478 Thousand SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 58.1 Million SEK | -1977.01% |
| Ziccum AB (publ) | 3.74 Million SEK | -32109.448% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 615.99 Million SEK | -95.925% |
| Sprint Bioscience AB (publ) | 50.48 Million SEK | -2290.587% |
| Mendus AB (publ) | 28.48 Million SEK | -4136.627% |
| Genovis AB (publ.) | 158.23 Million SEK | -662.733% |
| Intervacc AB (publ) | 8.01 Million SEK | -14957.867% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 4.37 Million SEK | -27492.318% |
| Active Biotech AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 170.44 Million SEK | -608.101% |
| Bio-Works Technologies AB (publ) | 43.89 Million SEK | -2649.426% |
| Aptahem AB (publ) | 2.63 Million SEK | -45777.974% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | 1.03 Million SEK | -116507.536% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -1567287.013% |
| Fluicell AB (publ) | 3.33 Million SEK | -36056.022% |
| Saniona AB (publ) | 16.84 Million SEK | -7066.793% |
| Lipigon Pharmaceuticals AB (publ) | 16.4 Million SEK | -7255.933% |
| Biovica International AB (publ) | 7.29 Million SEK | -16455.391% |
| Spago Nanomedical AB (publ) | 1.2 Million SEK | -100223.192% |
| AcouSort AB (publ) | 10.55 Million SEK | -11338.612% |
| Xintela AB (publ) | 78 Thousand SEK | -1547192.308% |
| Abliva AB (publ) | 137 Thousand SEK | -880840.146% |
| Egetis Therapeutics AB (publ) | 57.6 Million SEK | -1995.292% |
| Karolinska Development AB (publ) | 2.01 Million SEK | -59824.926% |
| OncoZenge AB (publ) | 3000.00 SEK | -40229500.0% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| 2cureX AB (publ) | 155 Thousand SEK | -778537.419% |
| CombiGene AB (publ) | 5.54 Million SEK | -21668.805% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Camurus AB (publ) | 1.71 Billion SEK | 29.703% |
| Corline Biomedical AB | 25.03 Million SEK | -4721.766% |
| IRLAB Therapeutics AB (publ) | 5.67 Million SEK | -21155.513% |
| Isofol Medical AB (publ) | 721 Thousand SEK | -167290.846% |
| I-Tech AB | 120.86 Million SEK | -898.575% |
| Hansa Biopharma AB (publ) | 134.09 Million SEK | -800.031% |
| Cyxone AB (publ) | 5.14 Million SEK | -23343.823% |
| ExpreS2ion Biotech Holding AB (publ) | 7.05 Million SEK | -17018.979% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 10.66 Million SEK | -11216.66% |
| Xspray Pharma AB (publ) | - SEK | -Infinity% |
| Elicera Therapeutics AB (publ) | 11.23 Million SEK | -10646.939% |
| Nanologica AB (publ) | 1.44 Million SEK | -83537.422% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 53 Thousand SEK | -2277047.17% |
| BioInvent International AB (publ) | 71.46 Million SEK | -1588.876% |
| Alzinova AB (publ) | 270 Thousand SEK | -446895.556% |
| Oncopeptides AB (publ) | 35.22 Million SEK | -3326.712% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -82392.926% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 2.82 Million SEK | -42667.116% |
| Simris Alg AB (publ) | 4.35 Million SEK | -27619.063% |
| Diamyd Medical AB (publ) | 130 Thousand SEK | -928275.385% |
| Xbrane Biopharma AB (publ) | 238.72 Million SEK | -405.547% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 23 Thousand SEK | -5247239.13% |